Fig. 5
From: S100β as a serum marker in endocrine resistant breast cancer
Combined endocrine and Src-kinase inhibitor treatment decreases tumor burden, which is marked by reduction in S100β. a In vivo model of endocrine resistant xenograft treated with dasatinib (50 mg/kg/day) in combination with tamoxifen showed a significant inhibition of tumor growth (mean tumor volume from caliper measurement, n = 7, error bars refer to 95% CI, p < 0.05). Representative IVIS images of mice at week 1 and week 7. Representative IVIS ex vivo images of tumor metastasis to lung, liver, and bone. b IHC analysis of tamoxifen-treated primary tumor from the endocrine resistant xenograft showed ERα expression and inhibition of Ki67, p-Src, SRC-1, HOXC11, and S100β expression after treatment with dasatinib. c Serum levels of S100β reduced in the xenograft mice treated with dasatinib at week 7 (n = 5, p = 0.085 one-tailed t test). d IHC revealed that dasatinib decreased expression of S100β and the proliferative marker Ki67 while maintaining the expression of ERα in an ex vivo explant model of tumor tissue from endocrine resistant patients after treatment with letrozole in the presence or absence of dasatinib (n = 2)